Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
VRTX stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
Vertex Pharmaceuticals Incorporated stock logo

Vertex Pharmaceuticals Incorporated

VRTX·NASDAQ

Last updated as of 2026-02-27 12:13 EST. Stock price information is sourced from TradingView and reflects real-time market prices.

Insights
Calculator
News

VRTX stock price change

On the last trading day, VRTX stock closed at 483.05 USD, with a price change of -0.90% for the day.
Trade stock perps

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

VRTX key data

Previous close483.05 USD
Market cap122.71B USD
Volume820.98K
P/E ratio31.50
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)15.33 USD
Net income (FY)−535.60M USD
Revenue (FY)10.98B USD
Next report dateFeb 12, 2026
EPS estimate5.110 USD
Revenue estimate3.18B USD USD
Shares float252.86M
Beta (1Y)0.22
Tokenized stocks

Have you heard of stock tokens?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

Vertex Pharmaceuticals Incorporated overview

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Reshma Kewalramani
Headquarters
Boston
Website
vrtx.com
Founded
1989
Employees (FY)
6.1K
Change (1Y)
+700 +12.96%
Revenue / Employee (1Y)
1.80M USD
Net income / Employee (1Y)
−87.80K USD

VRTX Pulse

Daily updates on VRTX stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• VRTX Stock Price 24h change: -0.90%. From 487.43 USD to 483.05 USD. The slight decline follows a period of consolidation after strong 2025 earnings results and 2026 revenue guidance of $12.95B–$13.10B, as investors weigh the scaling costs of new non-CF therapies.
• From a technical perspective, VRTX maintains a "bullish long-term trend" with the price currently holding above its 50-day ($462.72) and 200-day ($435.14) moving averages. Short-term indicators like RSI (56.40) and Stochastics are neutral, suggesting a healthy digestion of recent gains rather than a reversal. Support is firmly established in the $472–$479 range.
• Vertex reported blowout 2025 profits on Feb 25, with net income surging to $3.95 billion from a prior loss, driven by its cystic fibrosis (CF) franchise and initial traction from new launches like CASGEVY and JOURNAVX.
• Analysts at HC Wainwright and Barclays reiterated "Buy" and "Overweight" ratings this week with price targets as high as $607, highlighting the potential for non-CF products to contribute at least $500 million in 2026.
• BioMarin Pharmaceutical announced a definitive agreement on Feb 26 to acquire Amicus Therapeutics (FOLD), a major deal in the rare disease space that shifts the competitive landscape for established players like Vertex and AstraZeneca.
• Biotech stocks saw increased volatility on Feb 25 as several small-to-mid-cap companies, including Concord Biotech and Nautilus Biotechnology, experienced sharp intraday moves following positive trial updates and insider buying activity.
See more
about 1D ago
• VRTX Stock Price 24h change: -0.03%. From 483.13 USD to 483.00 USD.
• From a technical perspective, the stock is in a "strongly bullish" phase: it is trading above its 50-day ($463.58) and 200-day ($435.40) moving averages. While short-term indicators like the 5-day SMA suggest a minor pullback or consolidation, the long-term trend remains positive with the RSI at a neutral 55.46, indicating room for further growth before reaching overbought territory.
• Vertex announced it will participate in the TD Cowen 46th Annual Health Care Conference on March 3rd, where management is expected to provide updates on its diversified pipeline including pain and renal programs.
• The company reported a 945-share restricted stock vesting event for executive Jonathan Biller on February 24, following a series of standard Rule 144 insider dispositions earlier in the month.
• Analyst sentiment remains high with a "Strong Buy" consensus, as investors focus on the 2026 revenue guidance of $12.95B–$13.1B and the commercial rollout of non-cystic fibrosis products like Casgevy and Journavx.
• Twist Bioscience signed a co-exclusive licensing deal with Invenra for its bispecific antibody platform on February 25, reflecting a broader industry trend of large-cap biotech firms expanding their biologics discovery toolkits.
• Trinity Biotech secured a $25 million financing commitment on February 25 to support its R&D and commercial initiatives, signaling continued capital availability for innovation-driven healthcare firms.
See more
about 2D ago

VRTX stock price forecast

According to technical indicators for VRTX stock, the price is likely to fluctuate within the range of 515.81–651.76 USD over the next week. Market analysts predict that the price of VRTX stock will likely fluctuate within the range of 497.15–658.97 USD over the next months.

Based on 1-year price forecasts from 85 analysts, the highest estimate is 1034.43 USD, while the lowest estimate is 441.67 USD.

For more information, please see the VRTX stock price forecast page.

Latest VRTX stock news

These five software companies have the potential to see their stock prices double this year, according to Morgan Stanley

101 finance2026-02-11 20:57:28

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Revenue Surpasses Expectations

101 finance2026-02-12 21:21:34

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Finviz2026-02-12 21:33:42

Vertex Pharmaceuticals (VRTX) Stock Drops After Hours - Here's Why It's Trending Tonight

Finviz2026-02-13 04:15:36

Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?

Finviz2026-02-13 18:51:42

Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders

Finviz2026-02-16 13:54:05

Vertex Pharmaceuticals Stock: Does Wall Street Have an Optimistic or Pessimistic Outlook?

101 finance2026-02-17 08:27:11

5 Thought-Provoking Analyst Inquiries from Vertex Pharmaceuticals’ Fourth Quarter Earnings Conference

101 finance2026-02-19 10:36:49

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Finviz2026-02-19 17:33:45

Can Strategic Partnerships Drive CrowdStrike's Next Growth Phase?

Finviz2026-02-23 16:21:42

2 Nasdaq 100 Stocks You Should Watch and 1 That Raises Concerns

101 finance2026-02-25 12:21:55

Analyst Confidence Strong on Vertex (VERX) Following Fourth-Quarter Results

Finviz2026-02-26 00:07:16

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Finviz2026-02-26 12:03:47

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Finviz2026-02-26 12:03:47

Vertex to Present at Upcoming Conferences

Finviz2026-02-27 13:03:11

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of Vertex Pharmaceuticals Incorporated?

VRTX is currently priced at 483.05 USD — its price has changed by -0.90% over the past 24 hours. You can track the stock price performance of Vertex Pharmaceuticals Incorporated more closely on the price chart at the top of this page.

What is the stock ticker of Vertex Pharmaceuticals Incorporated?

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ, Vertex Pharmaceuticals Incorporated is traded under the ticker VRTX.

What is the stock forecast of VRTX?

We've gathered analysts' opinions on Vertex Pharmaceuticals Incorporated's future price. According to their forecasts, VRTX has a maximum estimate of 4830.50 USD and a minimum estimate of 966.10 USD.

What is the market cap of Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated has a market capitalization of 122.71B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock token prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Stock token perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially stock token perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official Fee overview or Announcement Center page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NASDAQ/
VRTX